EVIDENCE LIBRARY
Headache Review Found Ketamine–Midazolam Aura Results Did Not Extend to Aura Duration
A systematic review described one trial favoring intranasal ketamine over midazolam for aura severity. The same trial did not show superiority for aura duration.
A systematic review described one trial favoring intranasal ketamine over midazolam for aura severity. The same trial did not show superiority for aura duration.
The distinct outcomes
The review included five randomized trials and 193 participants across heterogeneous headache conditions, delivery routes, and comparison treatments. One intranasal trial reported reduced aura severity relative to midazolam without a corresponding duration advantage.
Other trials used different active treatments or saline and produced differing findings. The overall evidence quality was rated very low.
Do not merge endpoints or controls
Severity, duration, headache pain, and rescue-medication use are separate questions. A favorable result against an active control on one measure does not establish broad superiority across migraine outcomes.
Small samples, high or unclear risk of bias, and variation in administration limited synthesis. The review cannot establish midazolam as an effective migraine treatment or justify a universal ketamine regimen. For interpretation, retain the exact symptom endpoint, route, comparator, and patient group rather than restating a narrow aura finding as a general headache cure.
Source paper
Original analysis of the supplied journal article, identified as PMC8520840.